Bayer to make cure for blood stroke and St. Petersburg

Bayer, an international chemical and pharmaceutical concern, has launched a facility to produce diagnostic radiopaque contrast agents based on the Saint Petersburg site of LLC POLISAN Science & Technology Pharmaceutic Firm

Bayer to make cure for blood stroke and St. Petersburg

Bayer, an international chemical and pharmaceutical concern, has launched a facility to produce diagnostic radiopaque contrast agents based on the Saint Petersburg site of LLC POLISAN Science & Technology Pharmaceutic Firm.

In particular, POLISAN's capacities were utilized to arrange the production of such preparations as Gadovist, Magnevist and Ultravist that are used for diagnostics in computer and magnetic resonance tomography.

Test batches of the preparations are going to be made this year. The launching of the facility is scheduled for 2018.

As reported, a strategic partnership agreement and contrast agents production contract were executed between the companies in July 2015.

The day before, Bayer executed a production localization agreement in respect of another preparation to be made using POLISAN's capacities in Saint Petersburg, namely, heart disease drug called Xarelto. Commercial production is expected to be launched in 2019. The output is going to completely cover the Russian market's needs.

Moreover, on Wednesday, Nils Hessmann, the general representative of Bayer in Russia and CIS, told journalists that the company was going to expand its portfolio of Russia localized preparations and intended to agree with a local partner on localizing the production of oncological products in the Russian Federation within the year.

Previously, Bayer localized the output of pharmaceutical drugs based on the capacities of Medsyntez, an Ural facility. In particular, the production of Avelox, an antiinfective preparation, was launched in August 2015.